{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T19:18:02Z","timestamp":1778872682826,"version":"3.51.4"},"reference-count":57,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Joint Bone Spine"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1016\/j.jbspin.2012.01.004","type":"journal-article","created":{"date-parts":[[2012,2,25]],"date-time":"2012-02-25T07:11:11Z","timestamp":1330153871000},"page":"237-242","source":"Crossref","is-referenced-by-count":56,"title":["Therapeutic perspectives on uricases for gout"],"prefix":"10.1016","volume":"79","author":[{"given":"Ricardo P.","family":"Garay","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Raafat","family":"El-Gewely","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Pierre","family":"Labaune","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascal","family":"Richette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbspin.2012.01.004_bib0005","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jbspin.2010.02.027","article-title":"The genetic basis of hyperuricaemia and gout","volume":"7","author":"Merriman","year":"2011","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2012.01.004_bib0010","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1093\/oxfordjournals.molbev.a004123","article-title":"Loss of urate oxidase activity in hominoids and its evolutionary implications","volume":"19","author":"Oda","year":"2002","journal-title":"Mol Biol Evol"},{"key":"10.1016\/j.jbspin.2012.01.004_bib0015","doi-asserted-by":"crossref","first-page":"ii2","DOI":"10.1093\/rheumatology\/kep086","article-title":"New insights into the epidemiology of gout","volume":"48","author":"Doherty","year":"2009","journal-title":"Rheumatol"},{"key":"10.1016\/j.jbspin.2012.01.004_bib0020","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/ard.2006.055269","article-title":"EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR standing committee for international clinical studies including therapeutics (ESCISIT)","volume":"65","author":"Zhang","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2012.01.004_bib0025","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/ard.2007.076232","article-title":"Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005","volume":"67","author":"Annemans","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2012.01.004_bib0030","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1093\/rheumatology\/kem056a","article-title":"British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout","volume":"46","author":"Jordan","year":"2007","journal-title":"Rheumatol"},{"key":"10.1016\/j.jbspin.2012.01.004_bib0035","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/art.23007","article-title":"Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout?","volume":"57","author":"Perez-Ruiz","year":"2007","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.jbspin.2012.01.004_bib0040","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1186\/ar2738","article-title":"Gout. Novel therapies for treatment of gout and hyperuricemia","volume":"11","author":"Terkeltaub","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jbspin.2012.01.004_bib0045","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1126\/science.125.3254.937","article-title":"Uricolytic activity of purified uricase in two human beings","volume":"125","author":"London","year":"1957","journal-title":"Science"},{"key":"10.1016\/j.jbspin.2012.01.004_bib0050","unstructured":"EMA. European Medicines Agency. Rapport europ\u00e9en public d\u2019\u00e9valuation. Fasturtec. www.emeaeuropa.eu\/. 2001."},{"key":"10.1016\/j.jbspin.2012.01.004_bib0055","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.rhum.2006.10.020","article-title":"Efficacit\u00e9 et tol\u00e9rance de la rasburicase (Fasturtec) chez des patients goutteux intol\u00e9rants ou r\u00e9fractaires \u00e0 l\u2019allopurinol","volume":"73","author":"Bri\u00e8re","year":"2006","journal-title":"Rev Rhum"},{"key":"10.1016\/j.jbspin.2012.01.004_bib0060","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/ncprheum0214","article-title":"Successful treatment with rasburicase of a tophaceous gout in a patient allergic to allopurinol","volume":"2","author":"Richette","year":"2006","journal-title":"Nat Clin Pract Rheum"},{"key":"10.1016\/j.jbspin.2012.01.004_bib0065","first-page":"2093","article-title":"Rasburicase for tophaceous gout not treatable with allopurinol: an exploratory study","volume":"34","author":"Richette","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2012.01.004_bib0070","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1093\/ndt\/gfh629","article-title":"Urate oxidase (rasburicase) for treatment of severe tophaceous gout","volume":"20","author":"Vogt","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jbspin.2012.01.004_bib0075","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s10067-005-0043-y","article-title":"Rasburicase treatment in severe tophaceous gout: a novel therapeutic option","volume":"25","author":"Moolenburgh","year":"2006","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jbspin.2012.01.004_bib0080","unstructured":"FDA. Food and Drug Administration. Label and approval history KRYSTEXXA BLA 125293 Savient Pharm. 2010; www.fda.gov."},{"key":"10.1016\/j.jbspin.2012.01.004_bib0085","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1001\/jama.2011.1169","article-title":"Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients\u2019 refractory to conventional treatment","volume":"306","author":"Sundy","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.jbspin.2012.01.004_bib0090","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1002\/art.23810","article-title":"Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment failure gout","volume":"58","author":"Sundy","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2012.01.004_bib0095","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/art.22403","article-title":"Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout","volume":"56","author":"Sundy","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2012.01.004_bib0100","doi-asserted-by":"crossref","first-page":"3632","DOI":"10.1002\/art.23993","article-title":"Resolution of gouty tophi after twelve weeks of pegloticase treatment","volume":"58","author":"Baraf","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2012.01.004_bib0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.revmed.2011.02.007","article-title":"Traitement de la goutte","author":"Dubost","year":"2011","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.jbspin.2012.01.004_bib0110","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1093\/annonc\/mdf134","article-title":"Urate-oxidase in the prevention and treatment of metabolic complications in patients with B-cell lymphoma and leukemia, treated in the Soci\u00e9t\u00e9 Fran\u00e7aise d\u2019Oncologie P\u00e9diatrique LMB89 protocol","volume":"13","author":"Patte","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jbspin.2012.01.004_bib0115","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0037-1963(01)90039-3","article-title":"Urate oxidase in the prophylaxis or treatment of hyperuricemia: the United States experience","volume":"38","author":"Pui","year":"2001","journal-title":"Seminars Hematol"},{"key":"10.1016\/j.jbspin.2012.01.004_bib0120","first-page":"392","article-title":"Urate-oxidase for the treatment of tophaceous gout in heart transplant recipients. A report of three cases","volume":"62","author":"Rozenberg","year":"1995","journal-title":"Rev Rhum Engl Ed"},{"key":"10.1016\/j.jbspin.2012.01.004_bib0125","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0140-6736(10)60665-4","article-title":"Gout therapeutics: new drugs for an old disease","volume":"377","author":"Burns","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jbspin.2012.01.004_bib0130","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1177\/1078155209348719","article-title":"Rasburicase for the prevention and treatment of hyperuricemia in tumour lysis syndrome","volume":"16","author":"Kennedy","year":"2010","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.jbspin.2012.01.004_bib0135","doi-asserted-by":"crossref","first-page":"4207","DOI":"10.1200\/JCO.2009.26.8896","article-title":"Control of plasma uric acid in adults at risk for tumour lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone. Results of a multicenter Phase III study","volume":"28","author":"Cortes","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jbspin.2012.01.004_bib0140","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/MPH.0b013e318162bd41","article-title":"SFCE (Societe fran\u00e7aise de lutte contre les cancers et leucemies de l\u2019enfant et de l\u2019adolescent). Recommendations for the management of tumor lysis syndrome (TLS) with rasburicase: an observational survey","volume":"30","author":"Bertrand","year":"2008","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.jbspin.2012.01.004_bib0145","doi-asserted-by":"crossref","first-page":"4402","DOI":"10.1200\/JCO.2003.04.115","volume":"21","author":"Coiffier","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jbspin.2012.01.004_bib0150","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1756-185X.2008.00380.x","article-title":"Failure of rasburicase therapy in recurrent acute gout with tophi","volume":"11","author":"Hill","year":"2008","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.jbspin.2012.01.004_bib0155","first-page":"158","article-title":"A new method of the preparation of uricase and the effect of uricase on the blood uric acid levels of the chicken","volume":"21","author":"Altman","year":"1959","journal-title":"Arch Biochem"},{"key":"10.1016\/j.jbspin.2012.01.004_bib0160","first-page":"479","article-title":"Le traitement des hyperuric\u00e9mies en h\u00e9matologie par l\u2019urate-oxydase et l\u2019allopurinol","volume":"127","author":"Zittoun","year":"1976","journal-title":"Ann Med Int"},{"key":"10.1016\/j.jbspin.2012.01.004_bib0165","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0140-6736(81)90528-6","article-title":"Hypouricaemic effect of polyethylenglycol-modified urate oxidase","volume":"318","author":"Davis","year":"1981","journal-title":"Lancet"},{"key":"10.1016\/j.jbspin.2012.01.004_bib0170","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S0014-827X(00)00031-8","article-title":"Therapeutic proteins: a comparison of chemical and biological properties of uricase conjugated to linear or branched poly(ethylene glycol) and poly(N-acryloylmorpholine)","volume":"55","author":"Schiavon","year":"2000","journal-title":"Il Farmaco"},{"key":"10.1016\/j.jbspin.2012.01.004_bib0175","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/biot.200900218","article-title":"PEGylation of therapeutic proteins","volume":"5","author":"Jevsevar","year":"2010","journal-title":"Biotechnol J"},{"key":"10.1016\/j.jbspin.2012.01.004_bib0180","doi-asserted-by":"crossref","first-page":"114","DOI":"10.7326\/0003-4819-109-2-114","article-title":"Use of polyethylene glycol-modified uricase (PEG-uricase) to treat hyperuricemia in a patient with non-Hodgkin lymphoma","volume":"10","author":"Chua","year":"1988","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jbspin.2012.01.004_bib0185","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1681\/ASN.V1251001","article-title":"Diabetes insipidus in uricase-deficient mice: a model for evaluating therapy with poly(ethylene glycol)-modified uricase","volume":"12","author":"Kelly","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jbspin.2012.01.004_bib0190","unstructured":"Hershfield MS, Kelly SJ, inventors. Urate oxidase. US Patent 7,056,713 B1, Duke University. USA 2006."},{"key":"10.1016\/j.jbspin.2012.01.004_bib0195","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.addr.2007.06.011","article-title":"PEG-uricase in the management of treatment-resistant gout and hyperuricemia","volume":"60","author":"Sherman","year":"2008","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.jbspin.2012.01.004_bib0200","doi-asserted-by":"crossref","first-page":"R12","DOI":"10.1186\/ar1861","article-title":"Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase","volume":"8","author":"Ganson","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jbspin.2012.01.004_bib0205","unstructured":"FDA. Food and Drug Administration. Briefing Document for the Arthritis Advisory Committee Meeting. Arthritis Drugs Advisory Committee. 2010;UCM165714. (www.fda.gov\/)."},{"key":"10.1016\/j.jbspin.2012.01.004_bib0290","doi-asserted-by":"crossref","first-page":"14351","DOI":"10.1073\/pnas.1001072107","article-title":"Treating gout with pegloticase, a PEGylated urate oxidase, provides insight into the importance of uric acid as an antioxidant in vivo","volume":"107","author":"Hershfield","year":"2010","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.jbspin.2012.01.004_bib0215","doi-asserted-by":"crossref","unstructured":"Anderson A, Singh JA. Pegloticase for chronic gout. Cochrane Database Syst Rev. 2010;CD008335.","DOI":"10.1002\/14651858.CD008335.pub2"},{"key":"10.1016\/j.jbspin.2012.01.004_bib0220","unstructured":"3SBio. 3SBio acquires pegsiticase global rights from EnzymeRx for $6.25 million. The Medical News: News-Medical. Net; 2010."},{"key":"10.1016\/j.jbspin.2012.01.004_bib0225","unstructured":"FDA. Food and Drug Administration. Krystexxa (pegloticase). Risk evaluation and mitigation strategy (REMS). www.fdagov\/downloads. 2010."},{"key":"10.1016\/j.jbspin.2012.01.004_bib0230","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/00045391-200501000-00005","article-title":"Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective Inhibitor of xanthine oxidase in subjects with renal impairment","volume":"12","author":"Mayer","year":"2005","journal-title":"Am J Ther"},{"key":"10.1016\/j.jbspin.2012.01.004_bib0235","unstructured":"Horowitz Z. Puricase, first new drug treatment approach for gout in 40 years, could potentially revolutionise treatment for some. Medical News Today. 2006; www.medicalnewstoday.com."},{"key":"10.1016\/j.jbspin.2012.01.004_bib0240","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0002-9343(84)90743-5","article-title":"Severe allopurinol toxicity: description and guidelines for prevention in patients with renal insufficiency","volume":"76","author":"Hande","year":"1984","journal-title":"Am J Med"},{"key":"10.1016\/j.jbspin.2012.01.004_bib0245","unstructured":"Vidal. Zyloric. Dictionnaire Vidal. 2011:2581\u20132."},{"key":"10.1016\/j.jbspin.2012.01.004_bib0250","first-page":"S451","article-title":"Understanding treatments for gout","volume":"11","author":"Cannella","year":"2005","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.jbspin.2012.01.004_bib0255","doi-asserted-by":"crossref","first-page":"543","DOI":"10.2147\/TCRM.S6043","article-title":"New advances in the treatment of gout: review of pegloticase","volume":"6","author":"Reinders","year":"2010","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.jbspin.2012.01.004_bib0260","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1080\/08998280.2005.11928082","article-title":"Rasburicase (Elitek): a novel agent for tumour lysis syndrome","volume":"18","author":"Ueng","year":"2005","journal-title":"Proc Bayl Univ Med Cent"},{"key":"10.1016\/j.jbspin.2012.01.004_bib0265","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1345\/aph.1C336","article-title":"Rasburicase for the treatment and prevention of hyperuricemia","volume":"37","author":"Yim","year":"2003","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jbspin.2012.01.004_bib0270","series-title":"Biotechnology annual review","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S1387-2656(08)00007-0","article-title":"How to predict and prevent the immunogenicity of therapeutic proteins","author":"Schellekens","year":"2008"},{"key":"10.1016\/j.jbspin.2012.01.004_bib0275","series-title":"Site-specific encyclopedia of life sciences","author":"El-Gewely","year":"2005"},{"key":"10.1016\/j.jbspin.2012.01.004_bib0280","unstructured":"Vidal. Fasturtec. Dictionnaire Vidal 2011;87:826\u20137."},{"key":"10.1016\/j.jbspin.2012.01.004_bib0285","unstructured":"Comer B. Savient focuses on reimbursement for Krystexxa launch. Medical Marketing & Media. 2011."}],"container-title":["Joint Bone Spine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X12000085?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X12000085?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,12,30]],"date-time":"2021-12-30T23:00:39Z","timestamp":1640905239000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1297319X12000085"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":57,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["S1297319X12000085"],"URL":"https:\/\/doi.org\/10.1016\/j.jbspin.2012.01.004","relation":{},"ISSN":["1297-319X"],"issn-type":[{"value":"1297-319X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,5]]}}}